COQ2‐Associated Primary Coenzyme Q10 Deficiency Presenting With Proteinuria: A Case Report and Literature Review
Molecular Genetics & Genomic Medicine · 2026-07 · 14 (7)
DOI: 10.1002/mgg3.70221 ↗Kurz gefasst
Fallbericht in der Zeitschrift Molecular Genetics & Genomic Medicine, online erschienen am 06.07.2026. Verfasst von Yuqi Yue und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Children's Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Alkyl and Aryl Transferases, Ataxia, Mitochondrial Diseases, Muscle Weakness. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nanjing Special Fund for Health Science and Technology Development.
Abstract (Originalsprache)
Background
Primary coenzyme Q10 (CoQ10) deficiency (PCOQ10D) is an autosomal recessive mitochondrial disorder caused by pathogenic variants in genes involved in the CoQ10 biosynthetic pathway, including PDSS2 , COQ2 , COQ6 , and COQ8B/ADCK4 . Among these, pathogenic variants in the COQ2 gene impair oxidative phosphorylation and mitochondrial biogenesis in podocytes, often leading to encephalopathy and nephropathy.
Methods
Clinical data were collected from a pediatric patient with proteinuria caused by COQ2 gene variants, who was admitted to the Children's Hospital Affiliated to Nanjing Medical University in June 2025. Relevant examinations were completed, and whole‐exome sequencing (WES) was performed to screen for potential genetic variants in the patient's genomic DNA. Pathogenicity assessment of the identified variants was conducted in accordance with the American College of Medical Genetics and Genomics (ACMG) guidelines and online bioinformatics tools. Additionally, a systematic literature review on COQ2‐associated nephropathy was carried out in this study.
Results
The patient initially presented with global developmental delay accompanied by neurological lesions and developed proteinuria at 6 months of age. Genetic testing revealed two pathogenic variants: c.368G>A, p.(Arg123His) and c.908A>G, p.(Tyr303Cys). After oral administration of high‐dose CoQ10 (85 mg/kg/d) combined with enalapril maleate (0.80 mL/kg/d), the patient achieved complete remission of proteinuria and maintained stable renal function.
Conclusions
PCOQ10D exhibits marked phenotypic heterogeneity, characterized by variations in age of onset, organ involvement, and clinical severity, as well as significant interindividual differences in treatment responses to CoQ10 supplementation. This case expands the phenotypic spectrum of the disease. Moreover, the therapeutic outcomes suggest that all diagnosed patients require long‐term supplementation with adequate doses of CoQ10, which is of great significance for delaying disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Children's Hospital of Nanjing Medical University, Nanjing, China.
ORCID-Profile: Yuqi Yue
Förderung
- Nanjing Special Fund for Health Science and Technology Development
Zitieren
APA
Yue, Y., Zhao, F., & Chen, Q. (2026). COQ2‐Associated Primary Coenzyme Q10 Deficiency Presenting With Proteinuria: A Case Report and Literature Review. Molecular Genetics & Genomic Medicine, 14(7). https://doi.org/10.1002/mgg3.70221
Vancouver
Yue Y, Zhao F, Chen Q. COQ2‐Associated Primary Coenzyme Q10 Deficiency Presenting With Proteinuria: A Case Report and Literature Review. Molecular Genetics & Genomic Medicine. 2026;14(7). doi:10.1002/mgg3.70221
BibTeX
@article{Yue2026,
author = {Yue, Yuqi and Zhao, Fei and Chen, Qiuxia},
title = {COQ2‐Associated Primary Coenzyme Q10 Deficiency Presenting With Proteinuria: A Case Report and Literature Review},
journal = {Molecular Genetics & Genomic Medicine},
year = {2026},
volume = {14},
number = {7},
doi = {10.1002/mgg3.70221}
}
EUVIMED